Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
To observe the efficacy and safety of Chidamide combined with prednisone, cyclophosphamide, etoposide and methotrexate in relapsed or refractory PTCL.
Peripheral T-cell Lymphoma
DRUG: Chidamide|DRUG: prednisone|DRUG: Cyclophosphamide|DRUG: etoposide|DRUG: Methotrexate
Objective response rate, the total proportion of patients with complete response（CR or CRu）and partial response（PR）, every 8 weeks until 2 years after last patient's enrollment
Duration of response, Duration of complete response（CR or CRu）and partial response（PR）, every 8 weeks until 2 years after last patient's enrollment|Progress Free Survival(PFS), Time from treatment until disease progression or death, 2 years|Overall Survival, Time from treatment until death from any cause, 2 years
Prednisone, cyclophosphamide, etoposide, and methotrexate regimens are derived from a "metronidazole, etoposide, procarbazine and cyclophosphamide (PEPC) regimen" regimen that differs from the traditional "maximal Tolerance "chemotherapy, and the use of low-dose chemotherapy, frequent drug therapy, the purpose is to anti-angiogenesis and reduce drug resistance. At present, the program in our treatment of relapsed or refractory PTCL patients effective, safe and controllable, but also look forward to other joint treatment, so as to achieve better curative effect. To provide new treatment options for such patients.